Ensoma, a 5AM/F-Prime investment, is an in vivo gene editing platform company precisely engineering any or all hematopoietic and immune cells for a one-time, off-the-shelf treatment for a range of debilitating diseases.
In late 2021, Occam recruited Emile Nuwaysir, PhD, as the company’s first CEO. Previously, Emile served as CEO of BlueRock Therapeutics which was acquired by Bayer in 2019 for $1B.
